Literature DB >> 26431609

Kaposi Sarcoma-associated Herpesvirus: mechanisms of oncogenesis.

Thomas F Schulz1, Ethel Cesarman2.   

Abstract

Kaposi Sarcoma-associated Herpesvirus (KSHV, HHV8) causes three human malignancies, Kaposi Sarcoma (KS), an endothelial tumor, as well as Primary Effusion Lymphoma (PEL) and the plasma cell variant of Multicentric Castleman's Disease (MCD), two B-cell lymphoproliferative diseases. All three cancers occur primarily in the context of immune deficiency and/or HIV infection, but their pathogenesis differs. KS most likely results from the combined effects of an endotheliotropic virus with angiogenic properties and inflammatory stimuli and thus represents an interesting example of a cancer that arises in an inflammatory context. Viral and cellular angiogenic and inflammatory factors also play an important role in the pathogenesis of MCD. In contrast, PEL represents an autonomously growing malignancy that is, however, still dependent on the continuous presence of KSHV and the action of several KSHV proteins.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2015        PMID: 26431609     DOI: 10.1016/j.coviro.2015.08.016

Source DB:  PubMed          Journal:  Curr Opin Virol        ISSN: 1879-6257            Impact factor:   7.090


  57 in total

Review 1.  Multicentric Castleman disease: Where are we now?

Authors:  Hao-Wei Wang; Stefania Pittaluga; Elaine S Jaffe
Journal:  Semin Diagn Pathol       Date:  2016-05-16       Impact factor: 3.464

Review 2.  Insight into the Roles of E3 Ubiquitin Ligase c-Cbl, ESCRT Machinery, and Host Cell Signaling in Kaposi's Sarcoma-Associated Herpesvirus Entry and Trafficking.

Authors:  Binod Kumar; Arunava Roy; Mohanan Valiya Veettil; Bala Chandran
Journal:  J Virol       Date:  2018-01-30       Impact factor: 5.103

3.  Macaque homologs of Kaposi's sarcoma-associated herpesvirus (KSHV) infect germinal center lymphoid cells, epithelial cells in skin and gastrointestinal tract and gonadal germ cells in naturally infected macaques.

Authors:  Helle Bielefeldt-Ohmann; A Gregory Bruce; Kellie Howard; Minako Ikoma; Margaret E Thouless; Timothy M Rose
Journal:  Virology       Date:  2018-04-22       Impact factor: 3.616

4.  Induction of Kaposi's Sarcoma-Associated Herpesvirus-Encoded Thymidine Kinase (ORF21) by X-Box Binding Protein 1.

Authors:  Victoria Wang; David A Davis; Claire Deleage; Catherine Brands; Hong S Choi; Muzammel Haque; Robert Yarchoan
Journal:  J Virol       Date:  2020-02-14       Impact factor: 5.103

Review 5.  HIV-associated Kaposi sarcoma and related diseases.

Authors:  Priscila H Gonçalves; Thomas S Uldrick; Robert Yarchoan
Journal:  AIDS       Date:  2017-09-10       Impact factor: 4.177

6.  HACE1, an E3 Ubiquitin Protein Ligase, Mitigates Kaposi's Sarcoma-Associated Herpesvirus Infection-Induced Oxidative Stress by Promoting Nrf2 Activity.

Authors:  Binod Kumar; Arunava Roy; Kumari Asha; Neelam Sharma-Walia; Mairaj Ahmed Ansari; Bala Chandran
Journal:  J Virol       Date:  2019-04-17       Impact factor: 5.103

Review 7.  Molecular mechanisms of viral oncogenesis in humans.

Authors:  Nathan A Krump; Jianxin You
Journal:  Nat Rev Microbiol       Date:  2018-11       Impact factor: 60.633

8.  Full-Length Isoforms of Kaposi's Sarcoma-Associated Herpesvirus Latency-Associated Nuclear Antigen Accumulate in the Cytoplasm of Cells Undergoing the Lytic Cycle of Replication.

Authors:  H Jacques Garrigues; Kellie Howard; Serge Barcy; Minako Ikoma; Ashlee V Moses; Gail H Deutsch; David Wu; Keiji Ueda; Timothy M Rose
Journal:  J Virol       Date:  2017-11-30       Impact factor: 5.103

Review 9.  Control of Viral Latency by Episome Maintenance Proteins.

Authors:  Alessandra De Leo; Abram Calderon; Paul M Lieberman
Journal:  Trends Microbiol       Date:  2019-10-14       Impact factor: 17.079

10.  Control of B Cell Lymphoma by Gammaherpesvirus-Induced Memory CD8 T Cells.

Authors:  Nicholas K Preiss; Taewook Kang; Young-Kwang Usherwood; Yina H Huang; Bruce R Branchini; Edward J Usherwood
Journal:  J Immunol       Date:  2020-11-13       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.